ATE451466T1 - Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält - Google Patents
Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthältInfo
- Publication number
- ATE451466T1 ATE451466T1 AT98963811T AT98963811T ATE451466T1 AT E451466 T1 ATE451466 T1 AT E451466T1 AT 98963811 T AT98963811 T AT 98963811T AT 98963811 T AT98963811 T AT 98963811T AT E451466 T1 ATE451466 T1 AT E451466T1
- Authority
- AT
- Austria
- Prior art keywords
- heterologue
- fusion protein
- recombinant rhabdovirus
- rhabdovirus containing
- recombinant
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6847297P | 1997-12-22 | 1997-12-22 | |
| PCT/US1998/026084 WO1999032648A1 (en) | 1997-12-22 | 1998-12-22 | Recombinant rhabdovirus containing a heterologous fusion protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE451466T1 true ATE451466T1 (de) | 2009-12-15 |
Family
ID=22082797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98963811T ATE451466T1 (de) | 1997-12-22 | 1998-12-22 | Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6497873B1 (de) |
| EP (1) | EP1040198B1 (de) |
| JP (1) | JP4544497B2 (de) |
| AP (1) | AP1968A (de) |
| AT (1) | ATE451466T1 (de) |
| AU (2) | AU752004B2 (de) |
| BR (1) | BR9814370A (de) |
| CA (1) | CA2316033A1 (de) |
| DE (1) | DE69841372D1 (de) |
| IL (2) | IL136905A0 (de) |
| MX (1) | MXPA00006184A (de) |
| NZ (1) | NZ505312A (de) |
| OA (1) | OA11432A (de) |
| WO (1) | WO1999032648A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02002772A (es) * | 1999-09-17 | 2004-04-02 | Pro Virus Inc | Virus oncolitico. |
| WO2002016437A2 (en) * | 2000-08-24 | 2002-02-28 | Thomas Jefferson University | Rhabdovirus-based vectors to express high levels of functional human antibodies |
| EP1421222A4 (de) * | 2001-03-09 | 2004-07-07 | Univ California | Zellkultursystem zur synthese von infektiösem hepatitis-c-virus |
| EP1411880B1 (de) * | 2001-07-11 | 2018-04-25 | University of Miami | Rekombinante vsv zur behandlung von tumorzellen |
| US7820435B2 (en) * | 2002-02-06 | 2010-10-26 | Expression Technologies Inc. | De novo synthesized plasmid, methods of making and use thereof |
| US7731974B2 (en) * | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
| EP1606411B1 (de) | 2003-03-27 | 2008-12-10 | Ottawa Health Research Institute | Mutante vesicular stomatitis viren und deren verwendungen |
| KR20060017635A (ko) * | 2003-06-05 | 2006-02-24 | 와이어쓰 홀딩스 코포레이션 | 베네쥬엘라 말 뇌염 바이러스 레플리콘 벡터 및파라믹소바이러스 단백질 항원을 포함하는 면역원성 조성물 |
| EP1633860A2 (de) | 2003-06-09 | 2006-03-15 | Wyeth | VERBESSERTES VERFAHREN ZUR GEWINNUNG NICHTSEGMENTIERTER NEGATIV-STRANG-RNA-VIREN AUS cDNA |
| EP2064229B1 (de) * | 2006-09-15 | 2015-08-12 | Ottawa Hospital Research Institute | Onkolytisches rhabdovirus |
| US8961951B2 (en) * | 2007-07-06 | 2015-02-24 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
| US8703469B2 (en) | 2007-07-06 | 2014-04-22 | Boyce Thompson Institute For Plant Research | Baculoviruses with enhanced virion production and a method for the production of baculoviruses |
| EP2398496B1 (de) | 2009-02-20 | 2015-08-05 | International AIDS Vaccine Initiative | Vektoren des vesicular stomatitis virus, welche für epitope aus hiv env kodieren |
| EP2568289A3 (de) | 2011-09-12 | 2013-04-03 | International AIDS Vaccine Initiative | Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper |
| EP2586461A1 (de) | 2011-10-27 | 2013-05-01 | Christopher L. Parks | Von einem eingehüllten Virus abgeleitete Virenpartikel |
| US9347065B2 (en) | 2012-03-29 | 2016-05-24 | International Aids Vaccine Initiative | Methods to improve vector expression and genetic stability |
| WO2013158263A1 (en) | 2012-04-18 | 2013-10-24 | Mayo Foundation For Medical Education And Research | Replication-competent vesicular stomatitis viruses |
| FR2996856B1 (fr) * | 2012-10-15 | 2015-06-05 | Agronomique Inst Nat Rech | Novirhabdovirus recombinant utilisable comme vecteur d'antigenes |
| WO2018204694A1 (en) * | 2017-05-03 | 2018-11-08 | Biomarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells. |
| BR112018075281A2 (pt) | 2017-05-10 | 2020-02-11 | Wellstat Immuno Therapeutics, Llc | Vírus envelopado resistente à inativação pelo complemento para o tratamento de câncer |
| WO2021158878A1 (en) * | 2020-02-06 | 2021-08-12 | Boehringer Ingelheim Animal Health USA Inc. | Polypeptides useful for detecting anti-rhabdovirus antibodies |
-
1998
- 1998-12-22 WO PCT/US1998/026084 patent/WO1999032648A1/en active IP Right Grant
- 1998-12-22 US US09/217,967 patent/US6497873B1/en not_active Expired - Fee Related
- 1998-12-22 AT AT98963811T patent/ATE451466T1/de not_active IP Right Cessation
- 1998-12-22 NZ NZ505312A patent/NZ505312A/xx unknown
- 1998-12-22 AP APAP/P/2000/001852A patent/AP1968A/en active
- 1998-12-22 CA CA002316033A patent/CA2316033A1/en not_active Abandoned
- 1998-12-22 JP JP2000525566A patent/JP4544497B2/ja not_active Expired - Fee Related
- 1998-12-22 BR BR9814370-0A patent/BR9814370A/pt not_active Application Discontinuation
- 1998-12-22 EP EP98963811A patent/EP1040198B1/de not_active Expired - Lifetime
- 1998-12-22 DE DE69841372T patent/DE69841372D1/de not_active Expired - Lifetime
- 1998-12-22 MX MXPA00006184A patent/MXPA00006184A/es not_active IP Right Cessation
- 1998-12-22 IL IL13690598A patent/IL136905A0/xx active IP Right Grant
- 1998-12-22 AU AU19056/99A patent/AU752004B2/en not_active Ceased
-
2000
- 2000-06-20 IL IL136905A patent/IL136905A/en not_active IP Right Cessation
- 2000-06-21 OA OA1200000184A patent/OA11432A/en unknown
-
2002
- 2002-07-19 AU AU2002300207A patent/AU2002300207B2/en not_active Ceased
- 2002-10-23 US US10/277,997 patent/US20030138457A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6497873B1 (en) | 2002-12-24 |
| JP4544497B2 (ja) | 2010-09-15 |
| CA2316033A1 (en) | 1999-07-01 |
| NZ505312A (en) | 2003-01-31 |
| WO1999032648A1 (en) | 1999-07-01 |
| OA11432A (en) | 2004-04-26 |
| JP2001526901A (ja) | 2001-12-25 |
| IL136905A0 (en) | 2001-06-14 |
| BR9814370A (pt) | 2000-10-10 |
| AU752004B2 (en) | 2002-09-05 |
| EP1040198B1 (de) | 2009-12-09 |
| DE69841372D1 (de) | 2010-01-21 |
| MXPA00006184A (es) | 2003-02-11 |
| US20030138457A1 (en) | 2003-07-24 |
| AU1905699A (en) | 1999-07-12 |
| AP1968A (en) | 2009-04-30 |
| AU2002300207B2 (en) | 2006-07-13 |
| EP1040198A1 (de) | 2000-10-04 |
| IL136905A (en) | 2007-10-31 |
| AP2000001852A0 (en) | 2000-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE451466T1 (de) | Rekombinanter rhabdovirus, welcher ein heterologes fusionsprotein enthält | |
| GB9718609D0 (en) | Fusion protein | |
| TR199600357A2 (tr) | Rekombinant simanlik (Ob) proteinleri. | |
| DE69832542D1 (de) | Fusionsimplantat | |
| ID22425A (id) | Toksin-toksin protein insektisida dari xenorhabdus | |
| AU7274898A (en) | Recombinant antibody-enzyme fusion proteins | |
| NO2006014I1 (no) | Insulin glulisin | |
| NO2010013I1 (no) | Rekombinant FSH-CTP | |
| IS5375A (is) | KAY-nýstárlegt ónæmisprótín | |
| DE69823658D1 (de) | Ein laser | |
| AU2002300207A1 (en) | Recombinant Rhabdovirus containing a heterologous Fusion Protein | |
| AU8182298A (en) | Recombinant erythropoietin / immunoglobulin fusion proteins | |
| NO980566D0 (no) | Allergen-XCD32 fusjonsproteiner | |
| MX9909801A (es) | Metodo para separar proteinas de fusion | |
| AU9798398A (en) | Gfp-annexin fusion proteins | |
| DE69931010D1 (de) | Peptide mit osteogener Aktivität | |
| DE69938579D1 (de) | Extrazelluläre Matrixproteine mit modifizierten Aminosäuren | |
| EE04001B1 (et) | Peptiidne farmatseutiline kompositsioon | |
| BR9611734A (pt) | Proteina de fusão de ligante fas | |
| NO20021275D0 (no) | Transgent produserte fusjonsproteiner | |
| DE69705017D1 (de) | Medikamente bindendes Protein | |
| NO995062L (no) | <Beta>-anyloidpeptid-bindende proteiner og polynuldeotider som koder for samme | |
| BR9811344B1 (pt) | mÉtodo para aumentar a expressço de proteÍna exàgena. | |
| DE69823225D1 (de) | Fusionsproteine, bestehend aus proteinaseinhibitoren | |
| IL135942A0 (en) | Assay employing cadc fusion proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |